Your browser doesn't support javascript.
loading
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran.
Simon, A; Domanovits, H; Ay, C; Sengoelge, G; Levy, J H; Spiel, A O.
Afiliación
  • Simon A; Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
  • Domanovits H; Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
  • Ay C; Medical University of Vienna, Clinical Division of Hematology and Hemostaseology, Vienna, Austria.
  • Sengoelge G; Department of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
  • Levy JH; Department of Anesthesiology, Duke University, Durham, NC, USA.
  • Spiel AO; Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
J Thromb Haemost ; 15(7): 1317-1321, 2017 07.
Article en En | MEDLINE | ID: mdl-28426914
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Dabigatrán / Anticoagulantes Tipo de estudio: Etiology_studies Idioma: En Revista: J Thromb Haemost Asunto de la revista: HEMATOLOGIA Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Dabigatrán / Anticoagulantes Tipo de estudio: Etiology_studies Idioma: En Revista: J Thromb Haemost Asunto de la revista: HEMATOLOGIA Año: 2017 Tipo del documento: Article